Cochlear (ASX: COH) reaffirmed fiscal 2027 guidance for low-single-digit constant-currency revenue growth and $330 million to $350 million in underlying net profit. Developed-market implant volumes grew at a mid-single-digit rate from July to October, in line with management’s expectations.

Why it matters: After a disappointing fiscal 2026, conditions are stabilizing, with the recovery in fiscal 2027 tracking broadly in line with our unchanged forecasts.

  • Management tweaked its medium-term target, from 10% sales growth and an 18% net margin to about 10% annual underlying net profit growth.
  • We think the new target is aggressive and unlikely to be met. We assume revenue and profit compound annual growth rates of about 5% each to fiscal 2031, so management’s ambition needs faster growth or much higher margins than we forecast.

The bottom line: We maintain our $110 fair value estimate for wide-moat Cochlear. Shares are expensive, nearly 40% above our intrinsic assessment. The market appears to expect much faster penetration of seniors with hearing loss, higher margins, or both, than we do.

Big picture: The pool of untreated adults is enormous, with fewer than 5% of candidates having an implant. But early adopters have already come forward, and most of the rest wear hearing aids and are never referred, so each new patient is harder to win.

  • As such, we are not ready to bake in management’s 10% ambition. To justify the share price, we would need revenue growth of about 8% per year for five years, against the 6% we forecast for those years, and a net margin of about 18%, against our 14% forecast, which was last reached in fiscal 2019.

Winning seniors is slower and costlier

Cochlear is the market leader in cochlear implants with a consistent share of roughly 60% across developed markets. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth with developed-market adults as the next primary focus and emerging-market children after that.

We estimate roughly 65% of units are sold to developed markets and the remaining 35% to emerging markets, where over 90% are for children. Large price differentials in the lower range of products result in 80% of revenue being earned in developed markets and 20% in tender-oriented emerging markets. We estimate that average unit prices achieved in developed markets are roughly double those in emerging markets.

In the developed-market children segment, the growth tailwinds from increasing market penetration and the shift from single to bilateral implants over the last 15 years have played out, and we forecast growth in this segment to converge with the birthrate over time.

The adult developed market is more difficult to penetrate, and we expect the required investment to expand this segment will restrain significant operating margin expansion. Currently, penetration is still estimated to be under 5%, and Cochlear is at a pivot point as it invests to be adopted more widely by seniors with profound hearing loss. The prevalence of profound hearing loss increases over 65 years and has a steep increase over 80 years of age. As such, an aging population and low penetration suggest a large opportunity. However, hearing aids, not cochlear implants, are the standard of care. Cochlear is investing significantly to increase awareness and to fund research to support payer reimbursement. But we see two main challenges to accessing this market fully: first, the relatively low willingness of older candidates to undertake such invasive surgery, and second, the improvements in hearing aids. The hearing aid market is increasing its penetration in the severe hearing loss category, leaving only the smaller profound hearing loss as the cochlear implant niche.

Bulls say

  • There are signs Cochlear is looking to expand beyond the hearing market with the investment in Nyxoah, a company focused on hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea.
  • The annuity-like revenue stream from sound processor upgrades and accessories is an increasingly important component of the revenue stream.
  • Cochlear earns ROICs well ahead of its cost of capital, a testament to the company’s high quality.

Bears say

  • Growth in the cochlear implant market is becoming more costly to achieve, limiting the potential upside to earnings.
  • The arrival of low-cost competitor Nurotron could disrupt markets other than China, triggering price deflation.
  • Growth in emerging markets such as China, India, and Latin America weighs on margins due to lower average prices.